Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Mol Cancer Ther. 2021 Feb 25;20(5):915–924. doi: 10.1158/1535-7163.MCT-20-0228

Figure 2: Efficacy of NLG207 and enzalutamide in subcutaneous 22Rv1 xenografts after 3 weeks of treatment.

Figure 2:

Mice with subcutaneous 22Rv1 xenografts were treated for 3 weeks with the specified doses of vehicle controls, enzalutamide and/or NLG207, and euthanized at the completion of treatment. Average tumor volume measurements collected are plotted during the course of the study (A). Tumors, harvested following 3 weeks of treatment, were compared, as shown via photograph with one tumor per group (B), average tumor volume (C) and average tumor weight (D) at time of harvest; statistical comparisons to vehicle control above each treatment group are denoted: * - p<0.05. Daily average body weight measurements collected are summarized over the course of the study (E).